NCT05360615View on ClinicalTrials.gov

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

147

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

June 1, 2024

Study Completion Date

July 1, 2026

Conditions

Empagliflozin in Post AKI Stage 2-3

Interventions

DRUG

Empagliflozin 10 MG

SGLT2 inhibitors

DRUG

Placebo

Placebo

Trial Locations (1)

11000

Central Chest Institute of Thailand, Nonthaburi

All Listed Sponsors

lead

Chulalongkorn University

OTHER